<DOC>
	<DOCNO>NCT00635492</DOCNO>
	<brief_summary>Patients initiate injectable therapy type 2 diabetes ( insulin exenatide ) usual clinical practice enrol follow two year order describe actual practice regard time initial treatment regime , whether treatment regimen modify , treatment modification make , clinical patient-reported outcome .</brief_summary>
	<brief_title>CHOICE : CHanges Treatment Outcomes Patients With Type 2 Diabetes Initiating InjeCtablE Therapy</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>age 18 diagnosed type 2 diabetes treatment decision make within normal course care initiate either insulin exenatide treatment type 2 diabetes previously treat either insulin exenatide simultaneously participate another study include investigational drug procedure study entry fully inform give write consent use data sufficient understand primary language country able complete questionnaire .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>insulin</keyword>
	<keyword>exenatide</keyword>
	<keyword>Byetta</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>